[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100551336":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":10,"centralContacts":10,"locations":21,"responsibleParty":41,"collaborators":10,"id":45,"slug":10,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":46,"sex":52,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":58,"studyType":59,"phases":10,"briefSummary":60,"conditions":61,"keywords":10,"overallStatus":24,"whyStopped":10,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},{"fullName":5,"class":6},"Candiolo Cancer Institute - IRCCS","OTHER",[8,13],{"label":9,"type":10,"description":10,"interventionNames":11},"Patients",null,[12],"Other: Questionnaire",{"label":14,"type":10,"description":10,"interventionNames":15},"Controls",[12],[17],{"type":6,"name":18,"description":19,"armGroupLabels":20,"otherNames":10},"Questionnaire","none, it's a incidence-prevalence study",[14,9],[22],{"facility":23,"status":24,"city":25,"state":26,"zip":27,"country":28,"cosmosGeoPoint":29,"geoPoint":34,"contacts":35},"IRCCS Candiolo Cancer Center","RECRUITING","Torino","TO","10060","Italy",{"type":30,"coordinates":31},"Point",[32,33],11.99138,44.88856,{"lat":33,"lon":32},[36],{"name":37,"role":38,"phone":39,"phoneExt":10,"email":40},"Giada Pozzi, MD","CONTACT","+390119933017","giada.pozzi@ircc.it",{"type":42,"investigatorFullName":43,"investigatorTitle":44,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Giada Pozzi","MD","100551336",false,"NCT06458764","Sexual Dysfunction Check-up in Premenopausal Breast Cancer Survivors Taking Endocrine Therapy: A Cross-Sectional Study","SEXCHECK - Sexual Dysfunction Check-up in Premenopausal Breast Cancer Survivors Taking Endocrine Therapy: A Cross-Sectional Study","SEXCHECK","Inclusion Criteria:\n\n* women aged ≥18 and ≤ 55\n* who underwent surgery for early stage breast cancer\n* taking endocrine therapy for at least 3 months\n* providing an informed consent and completing the study questionnaires.\n\nExclusion Criteria:\n\n* withdrawal of the informed consent, at any time","FEMALE","18 Years","55 Years",{"count":56,"type":57},150,"ESTIMATED","1 Month","OBSERVATIONAL","Primary objectives:\n\n* To estimate Sexual Dysfunction (SD) incidence in premenopausal breast cancer patients treated by surgery and taking endocrine therapy.\n* To detect the presence of SD-related distress in the population, as a determining factor in the maintenance of a good quality of life.\n\nSecondary objectives:\n\n* To describe SD characteristics determining the most frequently reported symptoms and correlations with type of surgery or therapeutic regimens.\n* Collect baseline data for subsequent randomized trials involving practical interventions with the aim to reduce SD prevalence in this population.",[62,63,64],"Breast Cancer Female","Sexual Dysfunction","Premenopausal Breast Cancer","2025-06-18",{"date":67,"type":68},"2025-06-24","ACTUAL",{"date":70,"type":68},"2023-05-01",{"date":72,"type":57},"2025-12-01",{"name":5,"class":6},1]